Format

Send to

Choose Destination
J Pharm Biomed Anal. 2016 Jun 5;125:101-9. doi: 10.1016/j.jpba.2016.03.002. Epub 2016 Mar 3.

Analysis of bacopaside I in biomatrices using liquid chromatography-tandem mass spectrometry: Pharmacokinetics and brain distribution in Swiss-albino mice.

Author information

1
Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow , 226031 Uttar Pradesh , India; Academy of Scientific and Innovative Research, New Delhi 110001, India.
2
Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow , 226031 Uttar Pradesh , India.
3
Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow , 226031 Uttar Pradesh , India; Academy of Scientific and Innovative Research, New Delhi 110001, India. Electronic address: rabi_bhatta@cdri.res.in.

Abstract

Bacopaside I (BP-I) is the major pseudojujubogenin glycoside of Bacopa monniera (BM) extract which has been widely used as a nerve tonic to improve the memory and intellect of human beings from ancient times. A selective and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the quantification of BP-I in mouse plasma and brain homogenate has been developed and validated. All biosamples were processed by liquid-liquid extraction and chromatographed on C18- reversed phase column using mobile phase consisting of ammonium acetate (10mM, pH 4) - acetonitrile (10:90, v/v) at a flow rate of 0.5mL/min. The detection was performed in negative electrospray ionization mode and the precursor/product ion transitions of BP-I and internal standard (IS) hydrochlorothiazide were quantified in multiple reaction monitoring (MRM) using QTRAP-5500 MS/MS. The linearity was established over the concentration range of 0.5-2000ng/mL (r(2)>0.990), with lower limit of quantification (LLOQ) of 0.5ng/mL in both plasma and brain matrix. Within- and between-run precision and accuracy were well within the acceptable limits of variation. Consistent and reproducible recovery (>70%) was obtained with insignificant matrix effect for BP-I and IS. The method fulfilled US Food and Drug Administration (USFDA) guidelines for bioanalytical method validation in terms of selectivity, sensitivity, linearity, accuracy, precision, matrix effect, dilution integrity, carry-over effect and stability. Further, the method was successfully applied to execute the plasma pharmacokinetics and brain distribution of BP-I in Swiss-albino mice following intravenous administration at a dose of 5mg/kg.

KEYWORDS:

Bacopa monniera; Bacopaside I; Brain-to-plasma ratio; LC–MS/MS; Pharmacokinetics; Tissue distribution

PMID:
27017568
DOI:
10.1016/j.jpba.2016.03.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center